pharma · Syphilis · Human Immunodeficiency Virus
MEDA Pharma GmbH
MEDA Pharma GmbH & Co. KG
MEDA Pharma GmbH clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Bad Homburg, DE
- Employees
- 89
- Programs
- 8
- Drugs
- 28
- Patents
- 0
MEDA Pharma GmbH projects
5 ClinicalTrials.gov programs sponsored by MEDA Pharma GmbH.
MEDA Pharma GmbH has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BCN05-Bari
MEDA Pharma GmbH & Co. KG
Human immunodeficency virus
1 trial -
Lamivudina Aurovitas 300 mg comprimidos recubiertos con película EFG
MEDA Pharma GmbH & Co. KG
Mild Cognitive impairment due to Alzheimer Disease
1 trial -
Pacritinib
MEDA Pharma GmbH & Co. KG
Patients with myelofibrosis and platelets counts between 50 - 120 x 10e9/L
1 trial -
THALASSA 2.0
MEDA Pharma GmbH & Co. KG
post-COVID-19 Condition (PCC)
1 trial -
Veklury 100 mg powder for concentrate for solution for infusion
MEDA Pharma GmbH & Co. KG
COVID-10 infection
1 trial
Frequently asked questions
How many clinical projects does MEDA Pharma GmbH have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.